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Abstract
Cancer treatment has been the major goal of the gene therapy studies over
the decades.  Although there is  no cancer  gene therapy drug in the market
yet, substantial progress has been made in defining potential targets and in
developing  viral  and  nonviral  gene  delivery  systems  recently.  Numerous
genes have been studied as the targets for cancer gene therapy so far. Vari‐
ous  gene therapy strategies,  including suicide gene therapy,  oncolytic  viral
therapies, antiangiogenesis, and gene therapy vaccines have been developed.
The combination of  gene therapy with  conventional  methods,  such as  che‐
motherapy,  radiotherapy,  and  immunotherapy,  has  further  improved  the
therapeutic efficacy. Although the preclinical and experimental studies have
yielded highly encouraging results, there are still few gene therapy agents at
phase III trials. In the current chapter, we will review gene transfer systems,
targets, gene targeting strategies, and cancer gene therapy in the clinic.
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1. Introduction
The improvements in the past 20 years in the molecular biology have evoked optimism in
the treatment of cancer and yielded a number of targeted drugs in the market. However,
the curative treatment of the cancer has still  been possible with only the early diagnosis
and early intervention in the vast majority of the solid tumors. Almost half of the cancer
patients  diagnosed each  year  have  been  dying  of  the  disease  throughout  the  world.  In
particular,  the  patients  with  distant  metastasis  have  no  hope  of  cure  with  the  current
treatment modalities.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. Cancer is a complex genetic disease
It has long been suggested that the cancer has evolved from a single cell transformed by the
influence of the environmental factors such as physical, chemical factors, and viruses. Changes
in hundreds of genes, so-called mutations, are required to transform a normal cell into a cancer
cell. The major functional changes that transform a cell are mainly the activation of oncogenes
or inactivation of tumor suppressor genes.
The overexpression of oncogenes and loss of function of tumor suppressor genes usually
induce malignant transformation. Those changes are also required for further growth of tumor
cells.
A transformed cell usually gains some important biological properties to establish a malignant
disease. Those properties, including uncontrolled proliferation, evasion of growth suppres‐
sors, inhibition of apoptosis, replicative immortality, angiogenesis, proliferative signals,
invasion, and metastasis, are discussed in detail in a recent review of Hanahan and Weinberg
[1]. Although the conventional chemotherapy has mainly focused on direct tumor cell killing,
a vast majority of current targeted therapies have aimed to eliminate one or more of the above-
mentioned properties of cancer cells.
The targeting of angiogenesis, proliferation pathways, and immune system has yielded a
number of drugs that are already in the market. Nodules of cancer cells cannot grow beyond
1–2 mm without expanding their blood supply to access every increasing need for oxygen and
nutrients. In order to generate the additional blood supply, the tumor tissue stimulates the
elaboration of its own vessel network, through a process called angiogenesis [2]. If one could
cut the blood supply of the tumor, it cannot grow beyond 1–2 mm, which means that they
cannot grow enough to be diagnosed by the current diagnostic technology and cannot cause
a clinical disease. The tumor vascular targeting therapy or antiangiogenetic therapies like
bevacizumab and aflibercept targeting ligands of angiogenesis or small tyrosine kinase
inhibitors of angiogenesis pathway receptors or signaling molecules have already emerged as
standard therapeutic drugs in various tumors [3].
The overexpression of oncogenes and the loss of function of tumor suppressor genes are
usually involved in both malignant conversion of the cells and further growth of tumor cells.
A new generation of small molecules targeting proliferation pathways, like gefitinib, erlotinib,
and imatinib, has been developed to block the cancer-causing signals within cancer cells and
become standard treatments in those patients with mutations of EGFR or c-KIT [4]. Antibody
molecules, targeting the EGFR family of receptors like trastuzumab, cetuximab, and panitu‐
mumab also block the growth-promoting signals that push cancer cells into an unregulated
pattern of growth [5]. In contrast to standard chemotherapy, which is quite damaging to the
normal tissues of the body as well as the cancer tissue, the targeted drugs are quite specific for
the cancer cells and therefore relatively free of side effects.
Although majority of the cancer patients has a fairly intact immune system, the cells of the
immune system do not usually respond to tumor cells because the immune system cannot
differentiate the normal and cancer cells and therefore cannot fight against them. Immuno‐
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therapy or cancer vaccine therapy aims to activate immune system against tumors. Recently,
ipilumumab/tremelimumab and pembrolizumab/nivolumumab targeting checkpoints of
immune response such as CTLA-4 or PD1 have also been approved [6]. Likewise, a dendritic
cell-based vaccine, sipuleucel T, for the treatment of metastatic prostate cancer has been
approved 2 years ago [7].
Hundreds of genes have been involved in the action and regulation of those pathways. The
generation of cancer through a series of changes in the normal cellular genes makes the disease
a genetic disease at the cellular base. The involvement of genes in the development of the
disease also makes the disease a good candidate for gene therapy. Therefore, gene therapy has
emerged as the hope of curative treatment modality in cancer.
3. What is gene therapy?
Gene therapy can be defined as the delivery of genetic elements to the cancer cell or to the cells
of the immune response in order to correct the abnormalities in the cancer tissue or to induce
an immune response against the cancer cells. The corrective strategies can involve replacing
missing or defective genes, i.e., tumor suppressor genes [8], suppressing the action of cancer
promoting oncogenes [9], or programming normal or cancer cells to release into the systemic
circulation molecules which suppress the growth of cancer cells or their vasculature [10].
There are some prerequisites for a successful gene therapy program in cancer, such as a suitable
target to be replaced or modified, a carrier to reach the interest of gene to the cell, a successful
targeting of the vector, and a sufficient expression of the therapeutic genes in the target cells.
Besides a strong therapeutic efficacy, safety is also mandatory for the success of the treatment.
Unraveling the mystery of the genetic changes in the development of cancer has been proposed
many genes as targets for gene therapy studies. The second step in gene therapy following the
identification of a suitable gene is to introduce it into the target cell. Different vehicles (vectors)
have been used to introduce the genes into the cells, such as viral vectors, nonviral vectors,
and cell-based carriers. The mainly used viral vectors in cancer gene therapy are retroviruses,
adenoviruses, and adeno-associated viruses. The gene therapist uses the capability of the virus
to enter and reprogram the action of cells for purposes of therapy. The therapeutic genetic
element is first placed into a viral backbone to produce a complete therapeutic viral vector.
Alternatively, the therapeutic genetic elements can be delivered into the cancer cells through
droplets of fat called liposomes or nanoparticles. The genes themselves, in the form of naked
DNA or DNA packed into particles can be administered locally or systemically.
A third way of delivering genes to the target tissues is accomplished by using living cells such
as irradiated tumor cells, blood cells, and mesenchymal or neuronal stem cells. All of these
cells have the capability to home to particular types of target tissue through the blood stream.
In this way, the therapeutic genes can be placed into the brain or other target tissues because
of the homing properties of those cells.
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For the safety of the procedure and the increased therapeutic efficacy, the genes of interest
should be expressed in only target cells or tissues. Sparing of the normal cells and tissues is
one of the keystones in their clinical use. The target specificity of the vectors could be achieved
by the targeting of those specific to the tumor cells or tissues.
4. Gene transfer systems of cancer gene therapy
There are three main ways of transferring genes into the tumor cells: nonviral vectors, viral
vectors, and cell-based vehicles. For most of the tumors, a relatively short-term expression of
therapeutic genes may be sufficient to kill the tumor cells. Rapid clearance of viral vectors from
the blood stream has enabled the development of synthetic gene delivery vectors. However,
an important drawback for these approaches is to carry the DNA of interest to the distant
metastatic deposits. The nonviral gene delivery vectors have usually been injected locally to
the tumors. Although local injection is reasonable for tumors as melanoma, head and neck
cancers, or peritoneal carcinomatosis; it is not suitable in patients with hematogenous meta‐
stases. The limitations of the viral vectors are also valid for the nonviral vectors for gene
therapy. They have to survive through the blood stream to be arrested in the target tumor
tissue, to extravasate, and to bind to specific cells and to enter the cells and then to reach the
nucleus.
4.1. Nonviral vectors
Plasmid DNA, which is mostly used as nonviral gene therapy modality, is easily degraded by
nucleases [11]. Therefore, some strategies to reduce the size and prevent the degradation have
been developed. The most commonly used agents for gene delivery are cationic lipids [12]. The
cationic head group of the lipids binds to DNA and the lipid tail enables the collapse of the
DNA lipid complex [13]. Cationic lipid DNA complexes (lipoplexes) (LPD/DNA) enter the
target cell through an endosomal pathway. However, the transgene expression efficiency is
very low with lipoplexes. It has been shown that only a very small portion of the systemically
injected DNA could be reached to tumor tissue [14].
Lipid-based formulations of gene delivery have been predominantly limited to the intratu‐
moral or local applications. The systemic administration carries the potential risk of adverse
inflammatory and immune reactions. The development of systemic lipid delivery systems with
the modifications to reduce the systemic toxicity could have the potential for clinical use in
cancer gene therapy. In an animal model of breast cancer, folate-targeted lipid–protamine
DNA complexes (LPD-PEG-folate) have been shown to reduce the tumor volume and increase
the survival when administered systemically [14].
Neutral liposomes composed of DOPC (1,2-dioleyl-sn-phosphatidyl choline) and DOPE (1,2-
dioleyl-sn-phosphatidyl  ethanol  amine)  and  polycationic  carrier  proteins  as  protamine,
polylysine, polyarginine, polyhistidine, or polyethynilemine (PEI) are also suitable to carry
the  DNA [15–18].  The  hydrophobic  polymers,  such  as  polyethylene  glycol  (PEG),  polyhy‐
droxy propylmethacrylamide (pHPMA), and polyvinyl pyrrolidine (pVPyrr), have also been
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used to mask the positive charge of DNA to extend its half-life in the blood [19,20]. Both
the  neutral  liposomes  and hydrophobic  polymers  yield  less  toxicity  when administered
systemically.  The  leaky  nature  of  the  blood  vessels  of  the  tumors  allows  the  influx  of
macromolecules as polymer shielded DNA into the tumor. The PEGylation of plasmid DNA
has been reported to circulate in the blood several hours and passively accumulate in the
subcutaneous tumors in animals [21].
4.2. Viral vectors
Viruses have the natural ability to deliver the nucleic acids within its own genome to specific
cell types, including cancer cells. This ability makes those attractive and popular gene-delivery
vehicles. Retroviruses, adenoviruses, adeno-associated viruses, herpes simplex virus, poxvi‐
ruses, and baculoviruses are commonly modified and used as gene therapy vectors in cancer.
Additionally, chimeric viral-vector systems combining the properties of two or more virus
type are also developed.
Retroviral vectors derived from retroviruses contain a linear single-stranded RNA of around 7–
10 kb and have a lipid envelope. The viral particles enter the mammalian cells expressing
appropriate receptors for retroviruses [22]. After entering the cell, the viral reverse transcrip‐
tase transcribes the virus RNA into double-stranded DNA (dsDNS). The dsDNA transcribed
in the cytoplasm forms a nucleoprotein preintegration complex (PIC) by binding cellular
proteins [23]. The PIC migrates to the nucleus and thereby integrates the host genome. The
ability of transgene expression in only dividing cells is an advantage of retroviral vectors for
cancer gene therapy to avoid undesired expression in nondividing cells of surrounding tissues.
The incorporation of retroviral genes into the host genome provides long-term expression of
transgenes. Although this is advantageous, a nonspecific incorporation of viral DNA could
impair the function of host gene or induce aberrant expression of a cellular oncogene [24].
Although retroviral vectors have been the most widely used gene transfer vehicles in the clinic,
the risk of insertional oncogenesis seen in the trial of X-SCID infants in 2003 has limited the
use of retroviral gene transfer systems in humans [25]. The possibility of generating replication-
competent retroviruses is another safety issue regarding the clinical use of those vectors [26].
Lentiviral vectors derived from retroviruses can cause stable integration of the transgene into
the host genome with long-term gene expression. The ability of transducing both dividing and
nondividing cells make those vectors more suitable and efficient gene transfer vehicle over
retroviruses. Targeting strategies of vectors at the level of cell entry and transgene transcription
improved the use of lentiviral vectors in gene therapy trials [27]. However, the biosafety
concerns of random integration to the host genome as in retroviruses are the limitations of
those vectors.
Adenoviral vectors are widely used to introduce the therapeutic genes into the tumor cells. They
can infect a broad range of cell types, transfer the genes being not dependent on cell division,
and have high titers and high level of gene expression [28]. The most widely used serotypes
of adenoviruses to develop vectors in human cancer gene therapy studies are type 5 (Ad5) and
type 2 (Ad2). They have the capacity of approximately 8–10 kb of therapeutic genes with first-
Cancer Gene Therapy
http://dx.doi.org/10.5772/61775
5
generation vectors and up to 36 kbp with gutless third generation adenoviral vectors [29].
However, along with the immunogenic potential, the broad range of host cells by adenovirus
limits its systemic use in human cancer gene therapy trials [30]. Targeting strategies have
enabled the use of adenoviral vectors in human gene therapy trials. Adenoviral vectors cannot
integrate to cellular genome and express the transgene episomally. They cannot induce
random mutations. However, the transgene expression is limited to 7–10 days postinfection
[31]. Therefore, repeated administrations of the vector are needed to achieve sustainable
responses in cancer treatment. Adenoviruses could be engineered either as replication
deficient by deleting the immediate early genes of E1 or replication-competent keeping the E1
region. Replication-competent adenoviral vectors will be further discussed in the section of
oncolytic viruses.
Adeno-associated viruses (AAV) are simple viruses with approximately single-stranded DNA of
4.7 kb in size [32]. They belong to parvovirus family and require a helper virus such as
adenovirus or herpes virus for lytic replication and release from the cell [33]. They can infect
a wide variety of cells independent of cell cycle. This property makes AAV as suitable vectors
for cancer gene therapy. Furthermore, unlike adenoviruses, they elicit little immune response
when infect the normal host cells. Another advantage of AAV over adenoviruses is their ability
to integrate the transgene into a particular spot on the 19th chromosome of human cells [34].
Unlike retroviruses, AAV cannot induce mutations. However, the major drawback of AAV is
its limited cargo capacity of approximately 4 kbp of therapeutic genes. AAV could transduce
certain cell types. Therefore, targeting strategies such as modification of viral capsid proteins,
binding monoclonal antibodies, or bispecific proteins have been developed to improve the
efficiency of AAV systems in cancer gene therapy [35,36].
Baculoviruses are enveloped viral particles with a large dsDNA of approximately 80–180 kb.
They naturally infect insect cells. There have been no diseases related to baculoviruses in
humans. Along with their highly safety profile in humans, they seem very useful gene therapy
vehicles with their highly large cargo capacity of approximately 40 kb with possible multiple
inserts, easy manipulation, and production [37]. Autographa californica multiple nucleopoly‐
hedrovirus (AcMNPV) is the most widely used types of baculovirus in gene therapy studies.
It has a circular dsDNA genome of 135 kb [38]. They can easily transduce mammalian cells,
including many types of cancer cells, and cause high transgene expression in the host cell [39].
They are already approved for the production of human vaccine components such as Cervarix
(GlaxoSmithKline) in cervical cancer and Provenge (Dendreon) in prostatic cancer [40].
Herpes simplex virus (HSV) is a large DNA virus with approximately 152 kb of dsDNA genome.
It has a natural tropism to nerve tissues and cannot integrate into the host genome [41]. The
HSV vectors can be designed in three different types as amplicons, replication-defective, and
replication-competent vectors [42]. In general, the replication-competent HSV vectors are used
as oncolytic agents in cancer gene therapy studies [43].
Poxviruses were the first viruses to be used as gene therapy vectors. They have been used in
the in vitro production of proteins and as live vaccines. The attenuated forms of poxviruses
have been developed and used in the development of genetic cancer vaccine trials [44]. The
immunostimulatory properties of poxviruses make them preferable agents to induce immun‐
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ity against tumors. In particular, the attenuated MVA virus derived from chorioallantoid
vaccinia Ankara (CVA), a Turkish smallpox vaccine strain, has been widely used in cancer
vaccine development strategies [45].
5. Cells as the carriers of cancer gene therapy vectors
The systemic administration of the gene therapy vectors usually failed because of low titer
achieved in the target tissue and insufficient transgene expression. The clearance of the vector
by the immune system, sequestration, and nonspecific binding to nontarget tissues are the
major drawbacks of viral and nonviral vectors [46,47]. In general, in vivo targeting has relied
mainly upon the enhanced leakiness of the tumor vessels, allowing the extravasation and
access to tumor cells. Besides, the target tropism, extravasations in tumor site, and poor
penetration of the vectors into the tumor tissue are the major problems for the vectors to
eradicate the metastatic tumor deposits.
Cell carriers have the potential of eliminating those problems. They are stable and most of
them have tumor homing properties and can be administered locally, such as intraperitoneal
or intratumoral injections or systemically. In case of the use of autologous cells, they will not
be cleared by the immune system. Macrophages, bone marrow mesenchymal stem cells (MSC),
T cells, NK cells, and eosinophils are the known cells infiltrating the tumor tissues. Also, the
tumor cells themselves naturally have the potential of homing to the tumor deposits through‐
out the body.
Macrophages have been used to deliver therapeutic genes because of their naturally trafficking
ability to sites of neoplastic diseases [48]. Further refinement of the targeting of these cells by
using transcriptional promoters could avoid the transgene expression in other parts of the
body where the macrophages naturally traveled [49].
T cells can be used to transfer the therapeutic genes to target tissues because of their ability to
circulate through the body and arrest in tumor tissues [50]. T cells have the advantage of the
release of vectors that they carry in an antigen-binding-specific manner. The T cells could also
provide further antitumoral activity by their cytotoxic effects. Tumor infiltrating lymphocytes
(TIL) are the first example of cell-based carriers in cancer therapy in which they were trans‐
fected with cytokine genes [51].
Mesenchymal progenitor cells from either bone marrow (MSC) or adipose tissue (PLA) have
the potential to expand in culture and the differentiation along the adipogenic, osteogenic,
chondrogenic, and myogenic lineages [52,53]. It has been shown that lentivirally transfected
mesenchymal progenitors from the adipose tissue have sustained transgene expression, even
after the differentiation into adipogenic and osteogenic lineages [54]. Further modifications of
PLA cells transfected ex vivo in order to target tumor tissues of their natural potential
differentiation would provide an efficient gene delivery vehicle.
Some other cells such as fibroblasts and allogeneic cells have also been used as cell carriers for
gene therapy vectors [55,56]. Because of their homing properties to the tumor cell deposits,
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tumor cells could be good candidates to target the established metastases. An animal model
of MDA-MB-231 cells, transduced ex vivo by a CD carrying Ad vector, has been shown to
reduce the tumor volumes in the established metastases of the tumor [57].
6. Gene targeting in cancer gene therapy
In order to maximize the therapeutic index of cancer gene therapy, the expression of thera‐
peutic genes could be restricted to the target tissues. Therefore, the targeting of gene therapy
vectors is the major key for the success of those treatments. There are two main targeting
strategies: physical targeting and biological targeting.
6.1. Physical targeting
The first one is physical targeting by means of some physical methods such as local injections,
catheters, gene guns, and electroporation. This strategy is usually used for local delivery of
gene therapy vectors and is therefore not suitable for most of the cancer patients who may
have cancer spread throughout the body. Supercoiled DNA molecules and oligonucleotides
are also successfully delivered to the cells of the skin following intradermal injection to the
tumor deposits accessible by local injections. However, intratumoral injection might have only
the transducing capacity of the cells neighboring the needle. The tumor deposits in the body
cavities such as peritoneum, pleura, and meninges and in subcutaneous tissues are the
potential targets for the physical targeting of the gene therapy vectors in the clinic [58,59].
6.2. Biological targeting
In a second strategy, the viral or nonviral carriers of the genes are modified in such a way that
they can only bind to tumor cells but not the normal cells. Because of the low transduction
efficiency of the currently used gene therapy vectors in distant tissues when administered
systemically, the specific transgene expression or viral replication in target tissues could
provide an opportunity to achieve sufficient antitumor activity. To achieve this goal, tran‐
scriptionally and transductionally targeted vectors have been developed. For safety reasons,
mostly the replication defective vectors have been used to transfer the therapeutic genes into
tumor cells. However, because of limitations of vector delivery and relatively low levels of
gene transfer capacity, replication-deficient vector systems are usually inefficient for the
treatment of large solid tumors. Therefore, replicating vectors could efficiently transfer genes
and also increase the therapeutic efficiency by means of its oncolytic effect. Such vectors could
be targeted in such a way that they can replicate within the tumor cells but not in normal cells
and cause no local or systemic toxicity.
6.3. Transcriptional targeting
The clinical utility of a cancer gene therapy program will be dependent on its therapeutic index.
In order to maximize the therapeutic index, the expression of therapeutic genes could be
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restricted to the target tissues. The selective targeting of gene therapy vectors to specific cells
enables the delivery of therapeutic genes to the target cancer cells while sparing the normal
tissues. This has the potential of the reducing the dose of vectors and toxicity.
Transcriptional targeting, which utilizes DNA regulatory (promoter/enhancer) elements that
enable the expression of transgenes within specific cells, would probably decrease the toxicity
of the treatment while increasing the specificity. The promoters used to drive the transgenes
in viral or nonviral vectors targeted in cancer therapy could be tumor-selective, inducible, or
cell cycle regulated. Certain genes have been expressed specifically in tumors such as L-plastin,
survivin, telomerase, and midkine [60]. The vector constructs carrying tumor-specific pro‐
moters such as L-plastin, survivin, and midkine have been shown to efficiently eradicate tumor
cells while sparing normal cells [61–63].
Likewise, the tumor-type-specific group of selective promoters shows a pattern of tumor tissue
specificity. The promoters of oncofetal antigens such as carcinoembryonic antigen (CEA) and
alpha-feto protein (AFP), mucin 1 (muc1), and oncogenes such as c-erbB2 and MYC have been
used widely in the transcriptional targeting of gene therapy vectors to achieve specific
transgene expression in tumor tissue [64–68].
The phenotypically heterogeneous expression of certain genes in certain tissues constitutes the
basis of tissue-specific promoters in cancer gene therapy. The tissue specificity of those genes
is largely regulated at the transcriptional level. Therefore, the promoters of those genes have
been used to target cancer gene therapy vectors to specific tumor types in a specific manner
of their origin of tissues. The tissue-specific promoters such as PSA in prostatic cancer [69],
tyrosinase in melanoma [70], albumin in hepatocellular carcinoma [71], thyroglobulin (TG) in
thyroid cancers [72], glial fibrillary acidic protein (GFAP) in glioblastoma [73], and osteocalcin
(OC) in osteosarcoma [74] have been used to specifically target those tumors.
The inherent problems of tissue or tumor-specific promoters such as relative weakness and
lack of true restriction of gene expression to the tumor tissues have led to the use of new
promoters whose activity can be controlled exogenously. These systems also provide temporal
control of gene expression. Various stress genes of the body are usually silent under normal
conditions, but they are activated during the stress to protect the tissues. The stress genes up-
regulated during stress such as heat, hypoxia, glucose deprivation, irradiation, and chemo‐
therapy have opened a new avenue to the development of the tumor-specific targeting of gene
therapy. The use of human heat shock protein (HSP)-driven HSV-TK or CD suicide gene
therapy vectors has been a significant activity when combined with hyperthermia [75]. The
promoter region of the hypoxia-inducible factor (HIF-1), a key regulator of the transcriptional
response to oxygen, has been successfully used to target tumor cells [76]. MDR-1 gene encodes
a 170-kDa P-glycoprotein and belongs to the ATP-binding cassette (ABC) family of transport‐
ers, which mediates the transport of some chemo drugs out of the cells thereby decreasing the
efficacy of the treatment [77]. Therefore, the use of vector constructs carrying therapeutic genes
under the control of MDR-1 promoter could efficiently target chemo-resistant tumor cells [78].
Uncontrolled cell proliferation is the prominent feature of cancer cells. The retinoblastoma
family of proteins and their upstream regulators such as cyclin D, CDK4, and p16/INK4
regulate the G1 checkpoint in the cell cycle. Tumor suppression by Rb has been linked to its
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ability to repress E2F-responsive promoters such as E2F-1 promoter. It has been shown that
Ad vectors that contain transgenes driven by E2F-1 promoter can mediate tumor-selective gene
expression in vivo in glioma cells [79]. The promoters of cell cycle genes such as cyclin D, cyclin
A, cdc25c, cyclin-dependent kinase inhibitors, p16/INK4, p27, and p14 could be expected to
exert cell cycle arrest, thereby increasing the apoptosis when used in vector targeting strategies
in proliferating tumor or endothelial cells [80–83]. Additionally, drug-inducible systems such
as tat-on/tat-off regulated by tetracycline or rapamycin could provide a wide-dose response
range in the treatment [84].
6.4. Transductional targeting
The second strategy of biologic targeting is to engineer the either viral or nonviral vectors in
such a way that they can be captured only in tumor tissues, and therapeutic genes are produced
only in the environment of the tumor tissue. There have been numerous attempts to modify
the vectors with tumor cell-specific ligands that would increase the specific binding to tumor
cells and reduce the toxicity. Therefore, targeting DNA complexes to the tumor cell-specific
receptors is an attractive strategy. One of the well-known strategies is coating the surface of
the complexes with transferrin, an iron-binding plasma protein that is mainly an up-regulated
expression on rapidly proliferating cells as tumors [85]. Likewise, coating with EGF has also
been reported to cause a 50-fold increase in the transgene expression in hepatocellular
carcinoma cells [86]. The suicide gene HSV-TK/PEI complex mixed with a single chain
antibody (scFv) against EGFR with a negatively charged oligopeptide tail has exhibited EGFR-
specific gene transfer in vitro and in vivo [87].
The nonviral systems usually fail in promoting the delivery of DNA to the nucleus. Almost
99% of the internalized DNA from a nonviral vector is degraded in the cytoplasm [88].
Trafficking of exogenous DNA from cytosol to the nucleus may be improved by using the
nuclear localization signal (NLS) found in some nuclear proteins [89]. Dermaseptins, a family
of antimicrobial peptides that destabilize the membrane, have been successfully linked to NLS
of SV40-T antigen and HIV-1 Rev protein [90]. Likewise, mellitin, which is a membrane-active
protein, and viral protein r (vpr) of HIV-1, which binds directly to nucleoporins of the nuclear
pore complex, have been successfully bound to PEI/DNA complexes to improve nuclear
transport [91].
The selective targeting of viral vectors to specific cells permits the cell-specific expression
of transgenes and enables the systemic administration of the vectors. Avoiding the targeting
of the native receptor found on immune and inflammatory cell surfaces also reduces the
immunity  and  inflammation  to  those  vectors.  Replication-competent  retroviral  vectors
(RCR)  based  on  murine  leukemia  virus  (MLV)  represent  an  attractive  system  for  gene
delivery through their ability to replicate and provide long term transgene expression in
rapidly proliferating cells [92]. However, the uncontrolled spread of the RCR might cause
the infection of nontarget cells.  In order to develop tumor-selective RCR vectors, several
modifications have been made such as a modification of the envelope protein by insert‐
ing  single  chain  antibodies  (scFv)  [93]  and  peptide  ligands  [94].  Also,  the  specifically
targeted entry of replication-deficient retroviral vectors has been accomplished by combin‐
ing cell-specific monoclonal antibodies [95,96].
The  capability  of  an  Ad  vector  to  infect  a  cell  is  mainly  based  on  CAR  and  integrin
expression.  Following  the  attachment  of  an  adenoviral  vector  to  the  target  cell  via  C-
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terminal part of the fiber protein (knob) and CAR (Coxsackie’s B adenovirus receptor), the
alphaV beta3 and alphaV beta5 integrins mediate the internalization of the vector [97]. The
CAR deficiency of the primary tumor cells limits the success of the gene therapy proto‐
cols using Ad vectors [98]. Redirecting the Ad vectors to bind other cellular receptors would
allow CAR independent virus entry into the tumor cells. There are mainly two strategies
to  redirect  the  viral  vectors  to  the  cells:  conjugate-based  and genetically  modified  viral
membranes. Adenoviral vectors have been targeted to different cells by genetic modifica‐
tion of the capsid or by using adapter molecules. In the conjugate-based strategy, it is aimed
to  complex  the  vector  with  the  targeting  molecule  that  redirects  the  vector  to  the  cell-
specific  receptors.  Bispecific  molecules containing a first  specificity for the fiber knob to
block binding to CAR and the second specificity for a cell-specific receptor, such as bispecific
fusion proteins  (antibodies),  bispecific  peptides,  polymer mediated ligand coupling,  and
chemical  modifications  (biotin–avidin  bridges),  have  been  utilized  to  target  adenoviral
vectors [99–101].
Adeno-associated vectors (AAV) possess a highly favorable safety profile and have the unique
potential in certain cancer models. However, they have a restricted range of cells to transduce
transgenes to the target tissues. In order to augment the transduction efficiency of AAV in
various tissues retargeting strategies such as engineering of viral capsid, monoclonal antibod‐
ies and specific peptides have been used to successfully retarget the AAV vectors [102,103].
7. Targets for gene therapy of cancer
Current gene therapy studies have mainly focused on introducing the genes into the tumor
cells to block the action of oncogene expression and the development of tumor vasculature, or
to induce the development of an immune response against the cancer tissue. The major targets
of gene therapy are shown on Table 1.
Tumor suppressor genes (p53, RB, APC, BRCA1)
Oncogenes (RAS, BCL-2, MET, MYC, ERBB2, HPV E6E7, etc.)
Drug-metabolizing enzymes (cytosine deaminase, HSV-thymidine kinase, cytochrom p450, purine nucleoside
phosphorylase, carboxypeptidase A)
Direct cell killing (oncolytic vectors)
Angiogenesis (endostatin, angiostatin, VEGF, tissue factor, Tie2, etc.)
Cytokines (IL-2, IL-12, GM-CSF vb)
Immune system (T-cell receptor)/cancer vaccines (tumor-specific antigens, polynucleotide vaccines, genetically
modified dendritic cell-based vaccines, and adoptive immunotherapies)
Table 1. The major targets of gene therapy of cancer
7.1. Tumor suppressor genes
Loss of functions of tumor suppressor genes have crucial role in the development and spread
of cancer. Therefore, those genes were among the first targets of gene therapy studies. P53 is
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mutated in almost 60 percent of solid tumors. Reintroducing wild-type p53 has been one of
the common gene therapy approaches within the last two decades. The introduction of wild-
type p53 by retroviruses or replication-deficient adenoviral vectors into the cancer cells inhibits
tumor growth both in vitro and in vivo [104]. The use of adenoviral vectors carrying p53 has
yielded some clinical activities, particularly in patients with head and neck cancers and lung
cancers used either as a single agent or in combination with chemotherapy or radiotherapy
[105,106]. Likewise, strategies aiming at the activation of p53 pathway in patients with p53-
mutated tumors have also been tried. The introduction of small synthetic peptides like CDB3
derived from p53-binding protein 2 or p53 C terminal peptide have been shown to reactivate
the mutant p53 functions in vitro [107]. Furthermore, transductions of other family members
of p53 like p63 and p73, which are known to transactivate the downstream genes of p53
pathway, have been shown to induce apoptosis of tumor cells [108,109].
RB1 is a tumor suppressor gene involved in cell cycle regulation. Constitutively active RB1
potently inhibits cellular proliferation and induce persistent cell cycle arrest [110]. Since the
first cloning of the RB gene at the beginning of the nineties, researchers have tried to activate
the tumor suppressor function of the RB pathway. Gene transfer of truncated RB protein, such
as RB94, has been shown to restore the RB pathway and to induce potent tumor growth
inhibition both in vitro and in vivo [111]. However, these strategies have not been tested in the
clinical setting yet.
The restoration of functions of other tumor suppressor genes such as adenomatosis polyposis
coli (APC) in colorectal cancer cells [112] and BRCA1 in breast and ovarian cancers [113] has
been shown to slow the growth of tumor cells.
7.2. Oncogenes
The targeting of oncogenes has long been at the focus of drug development studies in cancer.
Small molecules of inhibitors of oncogene functions such as tyrosine kinase inhibitors have
already been used in the routine treatment of various cancers. Gene therapeutic strategies to
suppress oncogene functions are usually focused on the inhibition of those genes at mRNA
level. Usually small oligonucleotides or RNA inhibitors such as short-interfering RNA
(siRNA), short-hairpin RNA (shRNA), or micro-RNA (miRNA) have been used to interfere
the actions of oncogenes [114].
Chemically modified or unmodified small single-stranded DNA molecules, antisense oligo‐
nucleotides inhibit protein translation through the disruption of ribosome assembly or
utilization of RNase H enzymes to destroy mRNA. Numerous oligonucleotides and RNA
inhibitors have been designed to inhibit oncogenes, including RAS, MYC, BCL-2, or cell
signaling molecules survivin, IGF, VEGF, and PKCalphfa, have been tested. Although the
efficacy of these oligonucleotides has shown a great diversity, some of them have been tested
in phase II/III clinical trials in various cancer types [115]. Oblimersen, an antisense oligonu‐
cleotide targeting Bcl-2, is one of the oldest agents that have already tested in phase III studies
of Chronic Lymphocytic Leukemia CLL and multiple myeloma [116,117]. The members of the
RAS family of oncogenes have been found mutated in various solid tumors. Therefore, the
targeting of RAS would have been a hot topic in the development of recent therapeutics.
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Targeting RAS with an anti-RAS mRNA plasmid yielded significant tumor inhibition when
used alone or in combination with chemotherapy in hepatoma cells [118]. Antisense oligonu‐
cleotides targeting survivin, which are highly expressed in various cancer types, including
liver, lung, breast, and prostate, have been employed successfully to inhibit the expression of
the gene [119]. The phase I/II clinical trials have also shown some responses in cancers [120].
7.3. Gene-Directed Enzyme/Prodrug Therapy (GDEPT)
Conventional chemotherapeutic drugs are mainly directed to nonspecific direct cell killing.
However, dose-limiting toxicities avoid the use of higher doses of those drugs to eradicate the
disseminated cancer. However, if the drug was synthesized within the tumor tissue, then the
toxicity level would only increase in tumor cells but not other parts of the body. The tumor-
specific targeting of drug-metabolizing genes and the systemic use of a prodrug that is
converted to a cytotoxic agent by the action of transduced enzyme called gene-directed
enzyme/prodrug therapy (GDEPT) enable the achievement of that aim. GDEPT is also known
as suicide gene therapy. A lot of drug-metabolizing genes have been used to develop suicide
gene therapy/prodrug systems. Cytosine deaminase (CD) and herpes simplex virus 1 thymi‐
dine kinase (HSV1-TK) are the most widely studied ones in cancer gene therapy [121,122]. CD,
an enzyme found in fungi and bacteria, converts the nontoxic 5-fluorocyotsine into a toxic
chemotherapy drug of 5-fluorouracil. The lack of this enzyme in mammalian cells makes it a
convenient gene therapy tool to achieve intaratumoral chemotherapy. Others and we have
designed suicide gene therapy vectors to avoid systemic toxicity of 5-FU. We have shown that
Lp-driven CD carrying adenoviral vectors (AdLpCD) specifically target the epithelial cancers,
including breast, ovary, prostate, and lung [123]. It is possible to achieve a 5-FU dose in tumor
tissue as much as 200-fold of the dose when the drug is used intravenously at the standard
dose [123]. The 5-FU produced in the infected tumor cells can diffuse into the neighboring
tumor cells and kill them even not infected by the vector, which is called bystander effect [124].
Likewise, the combination of CD carrying vectors with conventional chemotherapy or
radiotherapy yields synergistic efficacy [125–127].
TK, one of the immediate early (IE) genes of HSV, converts ganciclovir (GCV) into a tri‐
phosphated form of GCV, which is an analogue of purine and inhibits DNA polymerase [128].
HSV1-TK suicide gene therapy loaded onto either adenoviral vectors or retroviral vectors has
been used to treat various tumors, including pancreatic cancer, hepatocellular carcinoma, lung
cancer, glioma, and leukemia [129–133]. Although the exact mechanism of HSV-TK carrying
vectors to kill tumor cells is not completely understood, they can induce apoptosis sensitizing
the TNF-related ligands or the sensitization of CD95-L, TNF-related apoptosis inducing
ligands may contribute to cell death [134]. The transcriptional targeting of HSV1-TK vectors
using tumor-specific promoters has decreased the potential side effects [130]. HSV-TK/GCV
prodrug systems have also been modified with other genes such as addition of E-cadherin to
increase the bystander effect of the vector [129].
Other prodrug-activating enzymes such as purine nucleoside phosphorylase to convert 6-
methylpurine-2-deoxyriboside to 6-methyl purine, cytochrome p450 cyclophosphamide and
ifosfamide to active metabolites of phosphoramide mustard and acrolein cyanide, and
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carboxypeptidase methotrexate-alpha peptides to methotrexate have also been reported to
decrease tumor burden in various preclinical models [135–137].
Dying tumor cells during suicide gene therapy could induce a tumor-specific immune
response. Therefore, combining prodrug/enzyme systems with an immnuomodulating
cytokine would further improve the efficacy. The addition of an IL-2 gene to the HSV-TK has
yielded more potent antitumoral activity when compared the each strategy alone [138].
Similarly, GM-CSF, IL-12, and IL-18 have also been used to increase the antitumoral activity
of suicide gene therapy [139,140]. Suicide gene therapy also successfully combines with other
strategies such as targeting tumor angiogenesis or adoptive transfer [141,142].
7.4. Oncolytic viral vectors
Viruses have long been recognized tumor cell lytic agents and tried to treat cancer patients.
However, the use of unmodified oncolytic viruses usually failed in the clinic. The engineering
of those viruses to increase their therapeutic index have been possible in the last two decades.
Herpes simplex virus (HSV), adenoviruses, parvoviruses, Newcastle disease virus, and
retroviruses have been modified as oncolytic viral vectors.
HSV with its high infective capacity of a large number of cell types has been one of the popular
oncolytic agents in the treatment of cancers. By deleting the genes thymidine kinase (TK),
ribonucleotide reductase (RR), or ICP34.5 alone or in combination, HSV vectors could be
selectively targeted many cancer types [143,144]. In order to further increase the cancer cell
specificity of the replicating vector, engineering of the expression of surface glycoproteins,
attachment of a novel receptor, or other macromolecules such as bispecific antibodies have
been tested [145]. Likewise, tumor cell-specific promoters to drive the immediate–early gene
expression, which is essential for viral replication, has been another effective strategy to obtain
tumor-selective HSV [146].
Adenoviruses can infect a wide variety of dividing and nondividing normal and tumor cells.
They can be engineered to have tumor-selective oncotropic properties or to be conditionally
replicative (CRAds) for selective cancer gene therapy.
In type I CRAds, usually a mutant Ad vector that replicates specifically in tumor cells with
aberrant cell cycle regulation has been developed. A deletion in the E1B 55-kDa region
abrogates the p53 binding of the vector, and therefore, the vector cannot replicate in cells with
intact p53 [147]. Therefore, this mutant Ad vector (dl1520) could replicate in only p53-deficient
tumor cells. However, further studies revealed that E1B 55-kDa mutant CRAds could also
replicate in p53 intact tumor cells [148,149]. The CRAds are already tested in phase II/III clinical
trials with some success in patients with p53-deficient tumors [150]. Accordingly, the combi‐
nation of CRAds with conventional treatment modalities provided better tumor control [151].
Although the combination of E1B-55kD mutant Ad vector with chemotherapy has yielded a
promising result of 63% partial response in patients with head and neck cancer administered
intratumorally [151], no objective responses were seen when the vector used alone [152,153].
Another way to achieve tumor-specific adenoviral replication is to take the advantage of
altered cell cycle regulation at G1-S phase checkpoint in which the retinoblastoma 1 (RB1] gene
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functions. In most of the cancer cells, there is a mutation in RB1 gene. Therefore, an Ad vector
having a mutation in the RB-binding site of E1A cannot induce the quiescent cells to pass the
checkpoint. A mutant CRAd carrying an E1A deletion, Ad5-∆24, is unable to replicate in
normal cells with the wild-type RB1 gene [154]. It has been shown that this E1A mutant Ad
vector has strong oncolytic activity in in vitro experiments of glioblastoma cells. Also, a similar
vector with E1A mutations at RB-binding sites (dl922-947) has also been shown to have strong
antitumor activity in other tumor models such as breast and colon cancer [155]. An additional
promising strategy to achieve specific oncolytic activity to the CRAds is the use of tumor-
specific promoters that drive the genes of the vector responsible for the replication, referred
to as type II CRAds. There have been many replication-competent vectors carrying tumor- or
tissue-specific promoters such as prostate-specific antigen (PSA), alphafeto protein (AFP),
Tcf4, MUC1, and CEA that have been developed [156–160]. We have designed replication-
competent adenoviral vectors carrying Lp-driven E1A, which are specifically replicated in
various tumor cell lines but not in normal cells [161]. We have also constructed a bicistronic
CRAd vector carrying both cytosine deaminase (CD) gene and E1A linked by an IRES
component driven by the Lp promoter (AdLpCDIRESE1A) [162]. The new bicistronic construct
also has been shown to have significant oncolytic activity in the colon (HTB-38), breast
(MCF-7), ovary (Ovcar 5], and prostate (LNCaP) cancer cell lines but not in normal human
mammary epithelial cells [162]. Also, the combination of the construct, AdLpCDIRESE1A/
5flourocytosine system, and chemotherapy has shown synergistic activity [163].
Different replication-competent viruses are currently being studied for their potential use in
cancer gene therapy. The naturally occurring tumor-selective viruses in their replication and
cytolysis might have the potential in cancer treatment. Autonomous parvoviruses (APV) have
been shown to replicate more efficiently in transformed cells than normal cells [164]. The
members of the rodent group of APVs such as LuIII, MVM (minute virus of mice), and H1,
which can infect human cells, are currently being studied as vectors for cancer gene therapy.
The replication of APV depends on cellular functions expressed during the S phase of the cell
cycle. The oncogenic transformation of cells favor the replication of APVs and therefore makes
them as oncolytic viruses [165]. The overexpression of the RAS signaling pathway [166] and
the defects in the interferon pathway of the transformed cells [167] could possibly enhance the
oncolytic activity of the APVs. Further manipulation of the specific targeting of those vectors
to achieve tumor-specific transgene expression such as inserting binding sites for the hetero‐
dimer beta-catenin/Tcf transcription factor to the MVM P4 promoter to make it responsive to
wnt signaling would make those attractive vectors for cancer gene therapy [168].
Newcastle disease virus (NDV) is an animal virus showing oncolytic activity in transformed
cells. In murine tumor xenograft models, the intratumoral administration of NDV has caused
significant tumor reduction [169]. Also, the intraperitoneal injection of the virus has resulted
in complete regressions of tumor xenografts. A replication-competent strain of NDV, PV701,
has been shown to replicate in tumor tissues of patients with solid tumors when administered
intravenously [170]. In that phase, trial objective responses have also been achieved at higher
and repeated doses of the virus.
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The murine hepatitis coronavirus (MHV), an oncolytic virus, is a positive-strand RNA virus
displaying strong species specificity with a replication cycle of 10–15 h and efficiently kills cells
by fusion of the infected cells with their neighboring cells [171]. Substituting its spike protein
by the other species such as porcine amino peptidase could change the host cell tropism of the
MHV. The resulting recombinant corona virus pMHV thus only infects porcine cells via the
porcine amino peptide N (pAPN) receptor. In vitro studies have shown that the tumor cells
could be more susceptible to that recombinant corona virus [172]. It is also likely to further
manipulate those vectors by using specific antibodies.
7.5. Tumor vascular targeting therapy
Unraveling the mechanisms of tumor-induced angiogenesis, which is a key event in tumor
growth and metastasis, has opened a new therapeutic era in cancer treatment. The antiangio‐
genic gene therapy approaches have been reported to inhibit the tumor-induced angiogenesis
and therefore tumor growth. The main strategies in antiangiogenic gene therapy are targeting
specifically the endothelial cells (direct antiangiogenic gene therapy) and interfering with a
tumor-derived angiogenic factor or the receptor for it or delivery of genes that encode
angiogenesis inhibitors (indirect antiangiogenic therapy).
Proangiogenic cytokines such as vascular endothelial growth factor (VEGF) and basic fibro‐
blast growth factor (bFGF) mainly secreted from tumor cells are required for the new vessel
formation. The indirect strategies were mainly focused on the inhibition of proangiogenic
cytokines or receptors involved in VEGF pathway or basic fibroblast growth factor (bFGF).
VEGF binds two high affinity receptors (VEGFR1/FLT-1 and VEGFR-2/KDR) that are ex‐
pressed on endothelial cells. An adenovirus-mediated transfer of a secreted form of the
extracellular domain of the FLT-1 (AdsFLT) has been shown to inhibit the growth of metastatic
tumor deposits when administered intravenously to preestablished splenic and liver meta‐
stases from a murine colon carcinoma cell line in syngeneic mice [173].
Likewise, the delivery of genes encoding antiangiogenic proteins such as endostatin, angios‐
tatin, platelet factor 4, interferon alpha, and thrombospondins have also been tested [174]. The
intratumoral administration of a plasmid encoding murine endostatin under the control of a
CMV promoter has provided elevated concentrations of endostatin high enough to obtain
growth arrest of murine renal carcinoma cells and breast cancer model [175]. Likewise, an
adenoviral vector carrying human endostatin gene markedly reduced the blood vessel density
of the tumor in an orthotopic liver tumor model [176].
The viral vector constructs of other angiogenesis inhibitors such as angiostatitn, thrombo‐
spondin, platelet factor 4, and hepatocyte growth factor antagonists have also been shown to
successfully inhibit endothelial cell proliferation and tumor growth [177–180]. However, there
are conflicting results regarding the tumor inhibiting activity of antiangiogenic gene therapy
modality in experimental models. The combination of antiangiogenic gene therapy with
chemotherapy or radiation could be an efficient way of the inhibition of tumor growth [181].
Many vector constructs carrying therapeutic or reporter genes driven by endothelium-specific
promoters such as preproproendothelin-1 (PPE-1), VEGFR kinase insert domain receptor
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(KDR), VEGF, E-selectin, and endoglin/CD105 have been reported to specifically target
endothelial cells [182,183]. The replication-competent adenoviral vectors driven by the
regulatory elements of FLK-1 and endoglin have successfully been targeted to the dividing
endothelial cells, and therefore, this strategy could be used as an antiangiogenic treatment for
cancer [184]. The activation of proapoptotic caspases such as caspase 9, driven by endothelium-
specific promoters such as VEGF and FGF, could be another strategy to destroy endothelial
cells [185].
Antisense approaches also are being tested for the inhibition of VEGF. A recombinant adeno-
associated virus (rAAV) vector encoding an antisense mRNA against VEGF has been shown
to inhibit the production of endogenous tumor cell VEGF [186]. The adenovirus-mediated
delivery of an uPA uPAR antagonist, which inhibits FGF, has been shown to inhibit angio‐
genesis-dependent tumor growth and metastasis in mice [187].
7.6. Immune system as the target of cancer gene therapy
The immune system is the most important defense mechanism of the body against cancer.
Recent developments in gene therapy have suggested to many cancer therapists that cytokine–
chemokine-based gene therapies, tumor antigen-specific vaccination strategies, and gene-
modified cellular therapies have great potential for future use either in the treatment of an
established disease or in the prevention of cancer in people having high risk of developing
cancer.
Cytokine/chemokine-based gene therapy has been widely used to induce immune system
against tumors. The delivery of immunomodulatory cytokines by gene therapy vectors has
opened a new avenue both to decrease the toxicity of these cytokines when used systemically
and to augment antitumor immunity. A wide variety of cytokines such as GM-CSF, IFN-a,
IFN-g, IL-2, IL-4, IL-12, IL-18, and IL-24 have been tested so far [188–191]. Also, the vector
constructs, including the combination of these cytokines, have also been tested in cancer. The
coexpression of IL-12 and GM-CSF has been reported to yield significantly more immune
response than the either cytokines alone [192]. In particular, implementing the cytokine genes
into oncolytic viruses has great potential for use in clinical trials [193]. Chemokines recruit the
immune effector cells to the tumor microenvironment. The delivery of chemokines such as
CCL-5 using viral vectors has also resulted in significant tumor reduction through increasing
tumor infiltration of DCs, macrophages, and CTLs [194].
Tumor-associated antigens (TAA) loaded on to gene therapy vectors have been tested in cancer
treatment (DNA vaccines) [195,196]. However, the efficacy of using TAA alone is not enough
to get a sufficient immune response to decrease tumor size. Therefore, researchers have focused
on the augmentation of the immune response by combining immune cytokines or costimula‐
tory molecules and TAA. This strategy seems much better than using either gene alone. We
have previously shown an increased efficacy of an adenoviral vector encoding a fusion protein
of CD40L and MUC1 in preclinical models [197]. The addition of prodrug/enzyme system to
DNA vaccination further increased the efficacy [198]. This strategy has also been tested in early
clinical trials with some success. Vector vaccinations using cytokines or costimulatory
molecules and tumor-associated antigens (TAA) have increased the immune responses and
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caused antitumor responses in preclinical models and even some responses in earlier clinical
trials. In a small clinical trial, an attenuated vaccinia vector carrying IL-2 and MUC1 has been
found effective in a small group of patients with advanced prostatic cancer [199]. Likewise, a
vector vaccine of canary poxvirus encoding B7.1 and CEA has been tested in a group of patients
with epithelial tumors [200]. Hundreds of different DNA vaccines have been tested in clinical
trials so far [202]. However, no DNA vaccine is available in the market.
Gene therapy vectors have also been used to transduce either autologous tumor cells or
dendritic cells. In the earlier studies, irradiated autologous tumor cells transduced to express
immunostimulatory molecules have been tested. In a syngeneic colon cancer model, the
subcutaneous injection of CT26 colon cancer cells transduced with an adenoviral vector
carrying GM-CSF gene has eliminated both the established tumors and prevented the growth
of new tumor nodules when rechallenged with tumor cells [201]. Later on, this strategy has
also been tested in human tumors. Autologous tumors transduced with GVAX, an adenovirus
carrying GM-CSF, have induced tumor-specific immunity in a variety of tumors, including
melanoma, prostate, and lung cancers [203]. Although a slight increase in overall survival has
been reported in those trials, no significant tumor responses observed [203,204].
The  ex  vivo  transduction  of  dendritic  cells  with  gene  therapy  vectors  carrying  either
immunostimulatory genes or TAAs is another promising strategy. When injected subcuta‐
neously,  the  dendritic  cells  exposed to  vectors  migrate  to  the  lymph nodes  where  they
prime cytotoxic T cells and induce a strong immune response. A number of vectors have
been designed to activate dendritic cells for the past two decades. We have tested the use
of ex vivo transduced dendritic cells with an adenoviral vector carrying a fusion protein
of  CD40L and MUC1 in a  syngeneic  mouse tumor model  [205].  The intratumoral  injec‐
tion of activated dendritic cells induced a potent tumor-specific T-cell response. Further‐
more, the combination of suicide gene therapy of a CD/5FU system and activated dendritic
cells  caused a more potent immune response and increased tumor response [205].  Like‐
wise,  retroviral  vectors  and lentiviral  vectors  are  both  used to  transduce  dendritic  cells
[206].  A  dendritic  cell  vaccine  based  on  the  ex  vivo  activation  of  mononuclear  antigen
presenting cells by a fusion protein consisting prostatic acid phosphatase and GM-CSF has
extended  the  progression-free  survival  of  patients  with  advanced  prostatic  cancer  and
approved by FDA in 2010 (Provenge®, Dendreon, USA) [207].
Recently, an adoptive therapy of cancer using genetically modified T cells armed with chimeric
antigen receptors (CAR) has gained great popularity with the announcement of success in
advanced malignancies [208]. CAR is a fusion receptor of an antibody-derived targeting
domain and T-cell signaling domain and expressed on T cells by a retroviral vector [209]. CARs
target antigens, including proteins, carbohydrates, and glycolipids without antigen processing
or HLA recognition. They can be generated in significant quantities ex vivo and used with the
minimal risk of autoimmunity or graft versus host disease [210,211]. However, because of the
severe side effects, the most troublesome being cytokine-release syndrome, researchers try to
obtain better CAR T cells with further refinement of receptor and better targets [212].
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8. Cancer gene therapy in the clinic—Future prospects
The vast majority of the clinical trials of gene therapy have been devoted to the treatment of
cancer so far. The gene therapy agents have been tested in many types of cancer in the clinic.
Almost 1200 clinical trials (approximately 64% of all gene therapy trials) in cancer have been
started, conducted, or completed [202]. Less than 4% of those are phase II or III and only few
of them are phase IV trials [202]. Although the preclinical and experimental studies have
yielded highly encouraging results, the progress in the clinic is not so remarkable. There is no
gene therapy agent available in the market yet.
The most important factor that has limited the success of clinical gene therapy trials in human
subjects is the delivery of the vector genetic elements or their products to the target cancer cells
and their vasculature. A second problem has been toxicity. Recent advances on improving the
delivery and specificity of gene therapy vectors have suggested these trials may be more
successful in the coming years. This is especially true of the attempts to use vectors to activate
the immune response against the tumor tissue. Continued testing of these strategies in the
context of clinical trials may lead to new opportunities for individuals engaged in a personal
struggle with cancer to control their disease.
Indeed, the nature of the distant spread of the disease, which causes the failure of conventional
treatment modalities, is also one of the main drawbacks of gene therapy of cancer.
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